Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

NCT02307500 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Pancreas Cancer
Ovarian Cancer
Melanoma
Sarcoma
Thymoma Type B3
Thymoma Type B2
Thymic Carcinoma

Interventions

DRUG: Regorafenib

Sponsor

Istituto Clinico Humanitas